Aletho News

Bill Gates’ CEPI revives Moderna mRNA Bird Flu vaccine development with $54M investment after HHS terminated funding

Avian influenza jab “mRNA-1018” is in full pandemic flight

By Jon Fleetwood | December 19, 2025

The Coalition for Epidemic Preparedness Innovations (CEPI) will invest up to $54.3 million to support a Phase 3 clinical trial for Moderna’s investigational mRNA-based pandemic H5 avian influenza “bird flu” vaccine candidate, mRNA-1018.

The move immediately follows the Gates Foundation’s $3.3 million award to a team of scientists at New York’s Rensselaer Polytechnic Institute (RPI) to develop “breakthrough purification technologies” for producing mRNA-based vaccines, which are plagued with contamination and impurity issues.

Bill Gates, through the Bill & Melinda Gates Foundation, is a co-founder and major funder of CEPI since its 2017 launch at Davos.

A Thursday press release from CEPI emphasizes the new mRNA bird flu vaccine is for “pandemic preparedness,” as this website has been documenting gain-of-function experiments being conducted on bird flu pathogens around the world, warning about the supranational orchestration of a coming bird flu pandemic.

HHS had terminated its multi-hundred-million-dollar commitment to Moderna to produce mRNA-1018 in May, with Moderna vowing to explore “alternative paths for development of the vaccine program.”

Moderna—also Gates-funded—has now followed through on its promise.

This is despite the fact that Moderna submitted data in November 2017 proving their mRNA vaccine lipid nanoparticles (LNPs) accumulate in mammalian liver, spleen, plasma (blood), kidneys, heart, and lungs.

Per the new CEPI press release:

The funding marks a significant step forward in global pandemic preparedness that could enable fast, equitable access to vaccines for one of the world’s most pressing health threats.

This Phase 3 study would be the first mRNA-based vaccine targeting pandemic influenza to enter a pivotal trial. If the vaccine candidate is licensed, it would expand the current global portfolio of H5 vaccines with a rapid-response platform that could revolutionize future pandemic responses, making a significant contribution to CEPI’s 100 Days Mission, a global goal to develop safe and effective vaccines within 100 days of a new pandemic threat being identified.

Dr Richard Hatchett, Chief Executive Officer of CEPI, stated:

“Pandemic influenza remains one of the greatest threats to global health security. With this partnership, we are not just advancing vaccine science, we are fundamentally changing the game. By harnessing the speed and adaptability of mRNA technology, we could shave months off the response time, deliver vaccines at scale, and enable equitable access for all. This is how we plan to protect the world from the next flu pandemic.”

Stéphane Bancel, Chief Executive Officer of Moderna, said:

“We are proud to have the support of CEPI to advance our pandemic influenza vaccine candidate, research that is critical to our commitment to pandemic preparedness. mRNA technology can play a vital role in addressing emerging health threats quickly and effectively, and we look forward to continuing our partnership with CEPI as we advance our health security portfolio, and in parallel, further the 100 Days Mission.”

CEPI collaborates closely with the World Health Organization (WHO)—also Gates-funded—through a 2017 Memorandum of Understanding, meant to accelerate pandemic vaccine development.

The WHO has already:

• Established a WHO-backed influenza command framework that merges governance, operational authority, and outbreak-response assets into a single controlling entity for the next pandemic cycle.
• Approved a WHO–Gates influenza-adjacent global digital ID and surveillance architecture, designed to track vaccination status and population compliance across borders during respiratory-virus campaigns.
• Ran pre-COVID compliance-testing programs tied to future influenza vaccine deployment, using CDC-, Gates-, and Oxford-linked institutions to model population behavior toward lower-quality vaccines years before SARS-CoV-2.
• Activated a “Future Pandemic” plan positioning U.S. labs inside a WHO-directed influenza sentinel surveillance network, preserving global monitoring operations even after the U.S. attempted withdrawal.
• Deployed a national influenza surveillance grid in Egypt under WHO authority, installing 30 sentinel sites and training 270 officers for real-time detection, reporting, and response.
• Constructed an international influenza pathogen-sharing command system enabling rapid transfer of H5- and other high-risk influenza samples for sequencing, analysis, and vaccine design under centralized WHO control.
• Outlined an influenza-triggered governance model that explicitly mandates “integration—merger of assets” and “united governance,” transferring all national governance functions to a single authority under conditions of crisis, uncertainty, or sector failure.

The WHO is already dictating how the coming bird flu pandemic will be controlled, just as it controlled the authoritarian COVID-19 pandemic response.

Moreover, the Trump administration this year announced a $500 million “next-generation, universal vaccine platform” called ‘Generation Gold Standard’ that will focus on bird flu jab creation.

Taken together, the CEPI–Moderna Phase 3 push, Gates-funded efforts to address known mRNA impurity issues, and the WHO’s already-built influenza surveillance, sample-sharing, and compliance architecture suggest a coordinated, pre-positioned pipeline designed to move seamlessly from pathogen research to mass deployment—before a bird flu emergency is formally declared.

December 20, 2025 - Posted by aletho | Deception, Full Spectrum Dominance, Science and Pseudo-Science | CEPI, Gates Foundation, United States